Previous 10 | Next 10 |
home / stock / govxw / govxw news
Advancing Phase 2 Clinical Trials for COVID-19 and Immuno-Oncology Evaluation of Company’s Vaccine Platform Against Monkeypox Underway ATLANTA, GA, Aug. 03, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NasdaqCM: GOVX), a biotec...
ATLANTA, GA, July 28, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer, announced today the publication of a peer-reviewed animal efficacy stu...
Conference Call to be Held Wednesday, August 3, at 4:30 p.m. Eastern Time ATLANTA, GA, July 26, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against infectious diseases and ca...
Operational Resources Strengthened to Support Company Growth and Development Atlanta, GA, June 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunother...
Company to Provide Updates on Phase 2 Clinical Trials for COVID-19 Vaccine and Immuno-oncology/Gedeptin® Atlanta, GA, June 07, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing hu...
Atlanta, GA, May 25, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, announced today that it has entered into a definitive agreement with a single healthcare-...
Atlanta, GA, May 24, 2022 (GLOBE NEWSWIRE) -- IND-Enabling Studies Underway in the United States for MVA-VLP-MUC1 Vaccine Candidate via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human immunotherapies and vaccines ...
Company Advancing Phase 2 Clinical Trials for COVID-19 and Immuno-Oncology ATLANTA, GA, April 27, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NasdaqCM: GOVX), a biotechnology company developing vaccines and immunotherapies against infectious dis...
GeoVax’s Unique Multi-Antigenic Vaccine Approach Designed to Provide Stronger, Broader Protection Against Malaria Atlanta, GA, April 26, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developin...
Conference call to be held Wednesday, April 27, at 4:30 p.m. Eastern Time ATLANTA, GA, April 19, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against infectious diseas...
News, Short Squeeze, Breakout and More Instantly...
GeoVax Labs Inc. Warrants Company Name:
GOVXW Stock Symbol:
NASDAQ Market:
GeoVax Labs Inc. Warrants Website:
Presentation Made During the 24th Annual World Vaccine Congress ATLANTA, GA, April 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced ...
ATLANTA, GA, March 28, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that its Chief Scientific Officer, Mark Newman, PhD, will presen...
ATLANTA, GA, March 12, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that its Chairman and CEO, David Dodd, will present at the 36t...